Azenta Inc

AZTA

Equity

ISIN null / Valor 1568240

NASDAQ (2025-11-21)

USD 34.89+16.3%

Azenta Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Azenta Inc, formerly known as Brooks Automation, is a leading provider in the life sciences sector, specializing in comprehensive sample management and genomic services for the biotech, pharmaceutical, and academic research markets. The company has developed a robust quality management system to meet the diverse needs of its customers, emphasizing its commitment to supporting scientific research and development. Azenta has been recognized for its innovative solutions, such as the Azenta Cryo Store Pico and the BioArc™ Ultra, which have garnered industry accolades for their design and functionality. These products exemplify Azenta's focus on developing automated, high-density, and eco-friendly ultracold sample management systems. Additionally, the company's selection by the Lupus Research Alliance to provide sample management services for the Lupus Nexus patient registry highlights Azenta's capability in supporting critical research initiatives. Through its advanced technologies and services, Azenta aims to enhance the efficiency and effectiveness of sample management in the life sciences, contributing to the acceleration of scientific discovery and therapeutic development.

Summarized from source with an LLMView SourceSector: Technology

Revenue Stability

Revenue from continuing operations remained flat at $144 million compared to the previous year. While Sample Management Solutions revenue declined by 4%, Multiomics revenue increased by 4%, reflecting a balanced performance across different segments.

Improved Profitability

Adjusted EBITDA for continuing operations rose to $18 million, with an adjusted EBITDA margin of 12.3%, marking a significant improvement from the previous year. Gross margin also increased to 47.1%, driven by favorable sales mix and enhanced cost execution.

Operational Efficiency

Operating expenses decreased by 6% year over year, thanks to reductions in selling, general and administrative expenses, as well as lower research and development costs. This cost management contributed to the overall margin expansion.

Guidance Reiterated

Azenta Inc reaffirmed its full-year fiscal 2025 guidance, expecting total organic revenue growth of 3% to 5% and an adjusted EBITDA margin expansion of approximately 300 basis points compared to fiscal 2024.

Summarized from source with an LLMView Source

Key figures

-23.4%1Y

-38.8%3Y

-48.1%5Y

Performance

54.7%1Y

50.2%3Y

51.3%5Y

Volatility